Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025
Rhea-AI Summary
Vivos Inc. (OTCQB: RDGL) reported record-breaking growth in its IsoPet® Animal Cancer Division for Q1 2025. The company's Precision Radionuclide Therapy™ treated 15 pets, marking a 150% year-over-year increase in treatment volume.
Key achievements include:
- Expansion to 14 certified clinics (8 small animal, 6 equine) with three new additions in Q1
- Breakthrough treatments in equine oncology, including four horses with ocular squamous cell carcinoma
- Biweekly production schedule of yttrium-90 hydrogel ensuring steady treatment supply
- Notable treatments at facilities like NorthStar Vets (NJ) and Brazos Equine Hospital (TX)
The company operates in the global veterinary oncology market, valued at $1.18 billion in 2023, with projected 11.3% CAGR through 2030. IsoPet® offers a non-invasive, single-session outpatient approach, positioning itself as a cost-competitive alternative to traditional radiation.
Positive
- Record 150% year-over-year increase in treatment volume (15 pets in Q1 2025)
- Expansion to 14 certified clinics from successful activation of 3 new facilities
- Operating in growing market valued at $1.18B with 11.3% CAGR through 2030
- Successful treatment expansion into equine oncology with novel applications
Negative
- None.
News Market Reaction – RDGL
In the trading session that priced this news, RDGL gained 7.14%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Kennewick, WA, April 23, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a leader in innovative cancer therapies, announced today a record-breaking first quarter for its IsoPet® Animal Cancer Division. The company’s patented Precision Radionuclide Therapy™ (PRnT™) treated an unprecedented number of pets in Q1 2025, marking a
Q1 2025 Highlights
1. Surge in Treatment Volume
IsoPet® treated 15 pets in Q1 2025, a
2. Breakthrough Clinical Applications
IsoPet® achieved groundbreaking advancements in equine oncology, treating four horses with ocular squamous cell carcinoma (SCC), including two with direct cornea injections—a novel approach for a condition with limited treatment options due to its sensitive location and high recurrence rate. Additional applications include palliative therapy for advanced equine jaw cancer and margin therapy post-tumor resection to reduce recurrence. These successes build on prior outcomes, such as a horse treated in 2022 that showed significant tumor atrophy within three months and a ferret successfully treated in 2024.
3. Clinic Expansion for Greater Access
Vivos Inc. activated three new certified clinics in Q1 2025, bringing the total to 14 (8 small animal, 6 equine). New additions include:
• Brazos Equine Hospital (Texas) – Specializing in equine cancers.
• Sumner Veterinary Hospital (Washington) – Focused on small animals.
• Animal Emergency & Specialty Center (Tennessee) – Serving small animals.
The company aims to “blanket the USA” with additional clinics in 2025, ensuring reasonable driving access for pet owners. Certified veterinarians, trained in precise Y-90 injections, are pivotal to IsoPet®’s success, as seen in treatments at Vista Veterinary Hospital (WA) and University of Missouri.
4. Strategic Marketing and Community Engagement
IsoPet® amplified its presence at major veterinary conferences, including VMX (Orlando) and WVC (Las Vegas), with plans to attend ACVIM, PacVet, VCS, and ACVS in 2025. Targeted newsletters and direct email campaigns have driven a measurable increase in treatment inquiries, while social media engagement, including posts by @IsoPetForCancer on X, highlights ongoing treatments and veterinary expertise. Community support is evident in user recommendations on X, with pet owners praising IsoPet®’s non-surgical approach.
5. Positioning in a Growing Market
The global veterinary oncology market, valued at
Leadership Perspective
Dr. Michael K. Korenko, President & CEO of Vivos Inc., stated:
“IsoPet® is transforming veterinary oncology by delivering safe, effective treatments that prioritize animal welfare. Our Q1 2025 achievements reflect a tipping point, fueled by word-of-mouth from satisfied veterinarians and pet owners, as well as growing international interest. We are committed to expanding access and exploring new applications. Our operational discipline is positioning our Isopet® division as a self-sufficient entity, which we believe is essential to maximize shareholder value. We are excited about the potential for strategic partnerships to elevate this division and accelerate growth.”
About IsoPet®
IsoPet® is a non-invasive, outpatient therapy that delivers high-dose beta radiation directly to solid tumors using Y-90 hydrogel. Suitable for cats, dogs, horses, and exotic animals, it targets cancers like sarcomas and equine sarcoids, with prior cases achieving complete tumor destruction and significant shrinkage. Certified clinics, rigorous vet training, and ongoing research ensure its efficacy and safety.
Pet owners seeking innovative cancer treatments can visit www.isopet.com to locate certified clinics, submit inquiries, or subscribe to our newsletter. Follow @IsoPetForCancer on X for real-time updates on treatments and advancements.
Contact Information
Michael K. Korenko, Sc.D.
President & CEO, Vivos Inc.
Email: MKorenko@RadioGel.com
Phone: (509) 736-4000
Website: www.isopet.com
Social Media: @VivosIncUSA, @IsoPetForCancer
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.’s control. For a detailed discussion of these risks, refer to the company’s filings with the Securities and Exchange Commission.
